A virtuosic performance from a master jazz musician is remarkable to see and hear on stage. Stick them in a MRI scanner while they play, and in addition to a great performance, we may be able to learn more about the circuitry of the brain.

Understanding tau behavior in Alzheimer’s disease could alter the course of diagnostics and therapy development. Research conducted in part by scientists at the Technische Universitat Munchen (TUM) has revealed an essential mechanism of tau deposition and neurodegenerative disease, the institution announced today.

Biomarkers built upon aptamers rather than peptides and antibodies offer multiple advantages for molecular imaging and several are currently under development, according to a review published Feb. 13 in the Journal of Nuclear Medicine.

The American Society of Nuclear Cardiology (ASNC) announced Feb. 27 that abstract submissions are now being taken for the upcoming ASNC 2014 meeting scheduled for Sept. 18-21 at the Seaport World Trade Center in Boston.

A treatment strategy for colon cancer combining molecular imaging, a radioimmunotherapy that seeks colon-specific anatomy and concomitant chemotherapy is being bundled as chemoradiotherapy to take out more metastatic disease, according to a study published online Feb. 20 in the Journal of Nuclear Medicine.

A reduction of the FDG maximum standardized uptake value is superior to visual analysis for the evaluation of treatment response in patients with Hodgkin's lymphoma, according to a study published online Feb. 24 in the Journal of Nuclear Medicine.

Varian Medical Systems out of Palo Alto, Calif., elected Andrew Eckert, 52, as head of the board of directors, the manufacturer of radiation oncology technology announced Feb. 20.

Patients who carry telltale genetic mutations are being targeted for expanded Parkinson’s research in a major study called the Parkinson’s Progression Markers Initiative, led by The Michael J. Fox Foundation, the advocacy group announced Feb. 25.